Inflammation and mortality in a frail mouse model

[1]  S. Leng,et al.  Inflammation and immune system alterations in frailty. , 2011, Clinics in geriatric medicine.

[2]  A. Salminen,et al.  Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. , 2010, Cellular signalling.

[3]  L. Fried,et al.  Associations of neutrophil and monocyte counts with frailty in community-dwelling disabled older women: Results from the Women’s Health and Aging Studies I , 2009, Experimental Gerontology.

[4]  C. Bult,et al.  Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels , 2009, Aging cell.

[5]  E. Kodesh,et al.  Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise. , 2009, Journal of applied physiology.

[6]  Marc Tatar,et al.  Can we develop genetically tractable models to assess healthspan (rather than life span) in animal models? , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[7]  R. Varadhan,et al.  Stimulus-response paradigm for characterizing the loss of resilience in homeostatic regulation associated with frailty , 2008, Mechanisms of Ageing and Development.

[8]  G. Kuchel,et al.  ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[9]  Andrzej Bartke,et al.  Impact of reduced insulin‐like growth factor‐1/insulin signaling on aging in mammals: novel findings , 2008, Aging cell.

[10]  K. Becker,et al.  The physical and biological characterization of a frail mouse model. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[11]  H. Yamaza,et al.  Role of Insulin and Growth Hormone/Insulin-Like Growth Factor-I Signaling in Lifespan Extension: Rodent Longevity Models for Studying Aging and Calorie Restriction , 2007, Current genomics.

[12]  D. Weigent,et al.  Protein hormones and immunity , 2007, Brain, Behavior, and Immunity.

[13]  S. Studenski,et al.  Research Agenda for Frailty in Older Adults: Toward a Better Understanding of Physiology and Etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults , 2006, Journal of the American Geriatrics Society.

[14]  N. Rosenthal,et al.  IGF-1, inflammation and stem cells: interactions during muscle regeneration. , 2005, Trends in immunology.

[15]  A. Bartke,et al.  Effects of caloric restriction on insulin pathway gene expression in the skeletal muscle and liver of normal and long-lived GHR-KO mice , 2005, Experimental Gerontology.

[16]  D. Cooper,et al.  IL-6-induced skeletal muscle atrophy. , 2005, Journal of applied physiology.

[17]  S. Leng,et al.  Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty , 2004, Aging clinical and experimental research.

[18]  K. Kelley.  From hormones to immunity: the physiology of immunology , 2004, Brain, Behavior, and Immunity.

[19]  L. Ferrucci,et al.  Inflammatory markers and physical performance in older persons: the InCHIANTI study. , 2004, The journals of gerontology. Series A, Biological sciences and medical sciences.

[20]  L. Ferrucci,et al.  Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  H. Cohen,et al.  Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. , 2003, The American journal of medicine.

[22]  L. Fried,et al.  Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. , 2002, Archives of internal medicine.

[23]  A. Yoshimura,et al.  Regulation of cytokine signaling and inflammation. , 2002, Cytokine & growth factor reviews.

[24]  Kathleen Koenig,et al.  Serum Interleukin‐6 and Hemoglobin as Physiological Correlates in the Geriatric Syndrome of Frailty: A Pilot Study , 2002, Journal of the American Geriatrics Society.

[25]  M. Tatar,et al.  A Mutant Drosophila Insulin Receptor Homolog That Extends Life-Span and Impairs Neuroendocrine Function , 2001, Science.

[26]  E. Hafen,et al.  Extension of Life-Span by Loss of CHICO, a Drosophila Insulin Receptor Substrate Protein , 2001, Science.

[27]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[28]  L. Guarente,et al.  Genetic pathways that regulate ageing in model organisms , 2000, Nature.

[29]  Luigi Ferrucci,et al.  Serum IL‐6 Level and the Development of Disability in Older Persons , 1999, Journal of the American Geriatrics Society.

[30]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[31]  Andrzej Bartke,et al.  Dwarf mice and the ageing process , 1996, Nature.

[32]  Richard A. Miller.  The Aging Immune System: Primer and Prospectus , 1996, Science.

[33]  D. Berg,et al.  Interleukin-10 gene knock-out mice: a model of chronic inflammation. , 1995, Clinical Immunology and Immunopathology.

[34]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[35]  G. Trinchieri,et al.  Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma- production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells , 1993, The Journal of experimental medicine.

[36]  R. Wanke,et al.  Effects of long-term elevated serum levels of growth hormone on life expectancy of mice: Lessons from transgenic animal models , 1993, Mechanisms of Ageing and Development.

[37]  E. Unanue,et al.  Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Banchereau,et al.  Interferon gamma inhibits interleukin 10 production by monocytes , 1993, The Journal of experimental medicine.

[39]  T. Mosmann,et al.  IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.

[40]  M. Goldman,et al.  Interleukin-10 , 2012, BioDrugs.

[41]  G. Trinchieri,et al.  Interleukin 10 (IL-10) Inhibits Human Lymphocyte Interferon 3,-Production by Suppressing Natural Killer Cell Stimulatory Factor/IL-12 Synthesis in Accessory Cells By Annalisa D'Andrea, Miguel Aste-Amezaga, , 1993 .